Montag A & Associates Inc. lowered its holdings in shares of Gilead Sciences (NASDAQ:GILD) by 33.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 39,886 shares of the biopharmaceutical company’s stock after selling 20,233 shares during the period. Montag A & Associates Inc.’s holdings in Gilead Sciences were worth $3,007,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Johnson Financial Group Inc. grew its stake in Gilead Sciences by 14.6% in the first quarter. Johnson Financial Group Inc. now owns 48,702 shares of the biopharmaceutical company’s stock valued at $3,672,000 after acquiring an additional 6,207 shares during the period. Mawer Investment Management Ltd. grew its stake in Gilead Sciences by 5.8% in the first quarter. Mawer Investment Management Ltd. now owns 719,997 shares of the biopharmaceutical company’s stock valued at $54,281,000 after acquiring an additional 39,517 shares during the period. Schwab Charles Investment Management Inc. grew its stake in Gilead Sciences by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 5,224,991 shares of the biopharmaceutical company’s stock valued at $393,913,000 after acquiring an additional 64,494 shares during the period. Wealthfront Inc. grew its stake in Gilead Sciences by 27.8% in the first quarter. Wealthfront Inc. now owns 27,453 shares of the biopharmaceutical company’s stock valued at $2,070,000 after acquiring an additional 5,974 shares during the period. Finally, Columbia Asset Management grew its stake in Gilead Sciences by 25.5% in the first quarter. Columbia Asset Management now owns 7,261 shares of the biopharmaceutical company’s stock valued at $547,000 after acquiring an additional 1,475 shares during the period. 78.16% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts have commented on GILD shares. Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, January 18th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $88.80 to $76.00 in a research note on Tuesday, January 30th. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 price objective for the company in a research note on Monday, February 19th. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Finally, Jefferies Group raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $81.19 to $93.00 in a research note on Friday, January 26th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and an average price target of $88.14.

Shares of Gilead Sciences opened at $67.60 on Friday, Marketbeat reports. The firm has a market cap of $87.83 billion, a P/E ratio of 7.90, a price-to-earnings-growth ratio of -5.87 and a beta of 1.19. Gilead Sciences has a 12 month low of $67.01 and a 12 month high of $67.62. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.75 and a current ratio of 2.84.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 EPS for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.19). The business had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.40 billion. Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The business’s revenue was down 21.8% compared to the same quarter last year. During the same quarter last year, the business posted $2.23 earnings per share. research analysts anticipate that Gilead Sciences will post 5.75 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Investors of record on Friday, June 15th will be issued a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $2.28 dividend on an annualized basis and a yield of 3.37%. Gilead Sciences’s dividend payout ratio (DPR) is currently 26.64%.

In related news, Director John Francis Cogan sold 5,833 shares of Gilead Sciences stock in a transaction on Monday, March 12th. The stock was sold at an average price of $80.93, for a total transaction of $472,064.69. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 14,435 shares of Gilead Sciences stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.54, for a total value of $1,177,029.90. The disclosure for this sale can be found here. Insiders have sold 241,102 shares of company stock worth $18,237,884 over the last quarter. 1.30% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.